Company
Headquarters: Ashiya, Japan
Employees: 732
CEO: Mr. Shin Ashida
¥77.38 Billion
JPY as of July 1, 2024
US$479.2 Million
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
AbbVie | $295.34 B |
AstraZeneca | $236.45 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
JCR Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic product, which includes GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. The company was incorporated in 1975 and is headquartered in Ashiya, Japan.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
JCR Pharmaceuticals Co. Ltd has the following listings and related stock indices.
Stock: JPX: 4552 wb_incandescent